RouteGenie Announces Inside the Lamp Live 2025: A Must-Attend Event for NEMT Professionals
Following the success of last year's inaugural event, Inside the Lamp Live 2025 will feature educational sessions, peer-led discussions, and product-focused workshops tailored to the real-world needs of NEMT professionals. The event will also provide an opportunity to connect with fellow transportation providers from across the country to share best practices and business strategies.
The timing of the event is especially strategic, as it takes place just before the NEMTAC Transform 2025 Annual Conference, held at the Hilton Anatole—directly across the street from the Sheraton Suites venue. This gives attendees the unique advantage of participating in both events during a single trip to Dallas.
'This isn't just a software conference—it's a platform where transportation providers can engage, grow, and redefine how they operate,' said Yurii Martynov, Marketing Director at RouteGenie. 'Inside the Lamp Live is about more than RouteGenie. It's about helping the entire industry collaborate and thrive.'
Inside the Lamp Live 2025 will cover a wide range of topics, including operational efficiency, compliance, staff training, dispatch management, billing optimization, and the latest RouteGenie feature updates. The event is open to both current RouteGenie users and NEMT companies exploring new technology solutions.
Registration is now open on Eventbrite: https://www.eventbrite.com/e/2025-inside-the-lamp-live-tickets-1364389709349
Long-time RouteGenie customers and a transportation provider exploring new solutions, Inside the Lamp Live offers an unmatched opportunity to grow, learn, and prepare for what's next in NEMT.
About RouteGenie:
RouteGenie is the premier software solution for Non-Emergency Medical Transportation providers. Built by industry experts, RouteGenie automates dispatching, routing, and billing to help transportation companies run smarter, scale faster, and serve better. To learn more about the software, please request an NEMT software demo.
Media Contact
Company Name: RouteGenie
Contact Person: Yurii Martynov
Email: Send Email
Country: United States
Website: https://routegenie.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
2 hours ago
- Globe and Mail
WKHS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Workhorse Group Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Workhorse Group Inc. (NASDAQ: WKHS) and Motiv Electric Trucks is fair to Workhorse shareholders. Upon completion of the proposed transaction, Workhorse shareholders will own approximately 26.5% of the combined company. Halper Sadeh encourages Workhorse shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether Workhorse and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Workhorse shareholders; and (2) disclose all material information necessary for Workhorse shareholders to adequately assess and value the merger consideration. On behalf of Workhorse shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Globe and Mail
2 hours ago
- Globe and Mail
1 Reason to Buy Robinhood Markets (HOOD) Stock
Key Points Robinhood is attracting new customers at a rapid clip. Revenue grew 45% in Q2, yet Robinhood still offers a limited range of services compared to big brokers. As it continues to roll out new features, Robinhood could see an avalanche of asset growth. 10 stocks we like better than Robinhood Markets › Robinhood Markets (NASDAQ: HOOD) is breaking a new mold in the fintech market. The stock has rocketed 490% higher over the past year, sending its market cap toward $100 billion. While the stock might look overbought after such a steep rally, its customer assets are still very small compared to other leading financial service companies, which leaves plenty of room for the company (and stock) to grow in value over the long term. The more services Robinhood brings customers, the more it grows Robinhood's platform assets have increased from $89 billion in the second quarter of 2023 to $279 billion in Q2 2025. With fee-generating services like Robinhood Gold continuing to gain traction, revenue grew 45% year over year in the second quarter to $989 million. This is why the stock is still a buy at these highs. Robinhood is seeing this much growth while offering limited services compared to big brokers like Schwab. As it catches up, Robinhood could grow into a multitrillion-dollar financial services company. Robinhood's pace of new announcements has been remarkable. In the first quarter, it rolled out index options to all customers, and it followed that up in the second quarter with the launch of stock tokens in Europe, allowing those customers to trade over 200 U.S. stocks in the form of tokenized contracts on a blockchain. By the end of the third quarter, Robinhood plans to launch its new banking service too. These are just a few of the many announcements the company has made recently. As it continues to launch new trading products, including its Cortex AI -powered trading tool later this year, its platform assets will likely continue to grow. There are several products, including fixed-income securities, that Robinhood can eventually tap into to further support its growth. For perspective, Schwab has over $10 trillion in client assets. I wouldn't bet against Robinhood CEO Vlad Tenev's ability to grow Robinhood into one of country's largest brokerage services. The stock still offers tremendous long-term upside. Should you invest $1,000 in Robinhood Markets right now? Before you buy stock in Robinhood Markets, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Robinhood Markets wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Charles Schwab is an advertising partner of Motley Fool Money. John Ballard has positions in Robinhood Markets. The Motley Fool recommends Charles Schwab and recommends the following options: short September 2025 $92.50 calls on Charles Schwab. The Motley Fool has a disclosure policy.
